115 related articles for article (PubMed ID: 26518748)
21. Bortezomib plus EPOCH is effective as frontline treatment in patients with plasmablastic lymphoma.
Castillo JJ; Guerrero-Garcia T; Baldini F; Tchernonog E; Cartron G; Ninkovic S; Cwynarski K; Dierickx D; Tousseyn T; Lansigan F; Linnik Y; Mogollon R; Navarro JT; Olszewski AJ; Reagan JL; Fedele P; Gilbertson M; Grigoriadis G; Bibas M
Br J Haematol; 2019 Feb; 184(4):679-682. PubMed ID: 29527667
[No Abstract] [Full Text] [Related]
22. Burkitt lymphomas failing dose-adjusted R-EPOCH (DA-R-EPOCH).
Aurer I; Bašić-Kinda S; Radman I; Ilić I; Grah JJ
Ann Hematol; 2014 Jan; 93(1):177-8. PubMed ID: 23636314
[No Abstract] [Full Text] [Related]
23. Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01.
d'Amore F; Relander T; Lauritzsen GF; Jantunen E; Hagberg H; Anderson H; Holte H; Österborg A; Merup M; Brown P; Kuittinen O; Erlanson M; Østenstad B; Fagerli UM; Gadeberg OV; Sundström C; Delabie J; Ralfkiaer E; Vornanen M; Toldbod HE
J Clin Oncol; 2012 Sep; 30(25):3093-9. PubMed ID: 22851556
[TBL] [Abstract][Full Text] [Related]
24. Long-term follow-up of dose-adjusted EPOCH plus rituximab (DA-EPOCH-R) in untreated patients with poor prognosis large B-cell lymphoma. A phase II study conducted by the Spanish PETHEMA Group.
Purroy N; Bergua J; Gallur L; Prieto J; Lopez LA; Sancho JM; García-Marco JA; Castellví J; Montes-Moreno S; Batlle A; de Villambrosia SG; Carnicero F; Ferrando-Lamana L; Piris MA; Lopez A
Br J Haematol; 2015 Apr; 169(2):188-98. PubMed ID: 25521006
[TBL] [Abstract][Full Text] [Related]
25. [Efficacy of modified B-NHL-BFM-90 protocol on anaplastic T-cell lymphoma in children and adolescents].
Sun XF; Zhen ZJ; Xiang XJ; Ling JY; Peng RJ; Xia Y; Zheng L; Luo WB; Lin H; Guan ZZ
Ai Zheng; 2009 May; 28(5):506-10. PubMed ID: 19624879
[TBL] [Abstract][Full Text] [Related]
26. [22-year-old man with T-cell-lymphoma and new skin lesions].
Kampfenkel T; Schroers R; Kreuter A
Dtsch Med Wochenschr; 2012 Mar; 137(9):429-30. PubMed ID: 22354798
[No Abstract] [Full Text] [Related]
27. Primary effusion anaplastic large cell lymphoma in a patient with long-standing dermatitis herpetiformis and celiac disease.
Nassiri M; Robertson MJ; Hertzberg L; Czader MB
Ann Hematol; 2013 Jan; 92(2):279-81. PubMed ID: 22915338
[No Abstract] [Full Text] [Related]
28. CD30(+) anaplastic large-cell lymphoma in children: analysis of 82 patients enrolled in two consecutive studies of the French Society of Pediatric Oncology.
Brugières L; Deley MC; Pacquement H; Meguerian-Bedoyan Z; Terrier-Lacombe MJ; Robert A; Pondarré C; Leverger G; Devalck C; Rodary C; Delsol G; Hartmann O
Blood; 1998 Nov; 92(10):3591-8. PubMed ID: 9808552
[TBL] [Abstract][Full Text] [Related]
29. Favorable outcome with doxorubicin-based chemotherapy and radiotherapy for adult patients with early stage primary systemic anaplastic large-cell lymphoma.
Zhang XM; Li YX; Wang WH; Jin J; Wang SL; Liu YP; Song YW; Ren H; Fang H; Zhou LQ; Chen B; Qi SN; Liu QF; Lu NN; Liu XF; Yu ZH
Eur J Haematol; 2013 Mar; 90(3):195-201. PubMed ID: 23301725
[TBL] [Abstract][Full Text] [Related]
30. Clinicopathologic, cytogenetic, and molecular studies of 13 Chinese Patients with Ki-1 anaplastic large cell lymphoma. Special emphasis on the tumor response to 13-cis retinoic acid.
Chou WC; Su IJ; Tien HF; Liang DC; Wang CH; Chang YC; Cheng AL
Cancer; 1996 Oct; 78(8):1805-12. PubMed ID: 8859196
[TBL] [Abstract][Full Text] [Related]
31. "Double-hit" of DUSP22 and TP63 rearrangements in anaplastic large cell lymphoma, ALK-negative.
Karube K; Feldman AL
Blood; 2020 Feb; 135(9):700. PubMed ID: 32106310
[No Abstract] [Full Text] [Related]
32. Epoch-cyclosporin A induces high response rates in relapsed lymphomas.
Lopez-Picazo JM; Gonzalez Manzano R; Ordoñez Tres JM; Jimenez MM; Calvo JP; Brugarolas A
Haematologica; 2000 Sep; 85(9):1003-4. PubMed ID: 10980651
[No Abstract] [Full Text] [Related]
33. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles.
Cunningham D; Hawkes EA; Jack A; Qian W; Smith P; Mouncey P; Pocock C; Ardeshna KM; Radford JA; McMillan A; Davies J; Turner D; Kruger A; Johnson P; Gambell J; Linch D
Lancet; 2013 May; 381(9880):1817-26. PubMed ID: 23615461
[TBL] [Abstract][Full Text] [Related]
34. Sequential multidrug chemotherapy (CHOP-VA-MB) in patients with high-grade non-Hodgkin's lymphoma--a 20-year follow-up.
Björkholm M; Celsing F; Johansson E;
Ann Hematol; 2006 Oct; 85(10):731-3. PubMed ID: 16838163
[No Abstract] [Full Text] [Related]
35. Use of targeted therapy for refractory ALK-positive anaplastic large cell lymphoma as a bridging strategy prior to allogeneic transplantation.
Ordemann R; Stöhlmacher J; Beuthien-Baumann B; Platzek I; van den Hoff J; Kroschinsky F; Middeke JM; Platzbecker U; Zietz C; Bornhäuser M; Ehninger G
Ann Hematol; 2013 Jan; 92(1):125-7. PubMed ID: 22820970
[No Abstract] [Full Text] [Related]
36. Successful treatment of an elderly Langerhans cell sarcoma patient by EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin) chemotherapy.
Matsukawa T; Suto K; Miyoshi H; Oshimi K; Ohshima K; Miyagishima T
J Clin Exp Hematop; 2018 Dec; 58(4):184-187. PubMed ID: 30305476
[No Abstract] [Full Text] [Related]
37. Dose-intense chemotherapy every 2 weeks with dose-intense cyclophosphamide, doxorubicin, vincristine, and prednisone may improve survival in intermediate- and high-grade lymphoma: a phase II study of the Southwest Oncology Group (SWOG 9349).
Blayney DW; LeBlanc ML; Grogan T; Gaynor ER; Chapman RA; Spiridonidis CH; Taylor SA; Bearman SI; Miller TP; Fisher RI;
J Clin Oncol; 2003 Jul; 21(13):2466-73. PubMed ID: 12829664
[TBL] [Abstract][Full Text] [Related]
38. Co-existent primary cutaneous anaplastic large cell lymphoma and lymphomatoid papulosis.
Dawn G; Morrison A; Morton R; Bilsland D; Jackson R
Clin Exp Dermatol; 2003 Nov; 28(6):620-4. PubMed ID: 14616830
[TBL] [Abstract][Full Text] [Related]
39. Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial.
Récher C; Coiffier B; Haioun C; Molina TJ; Fermé C; Casasnovas O; Thiéblemont C; Bosly A; Laurent G; Morschhauser F; Ghesquières H; Jardin F; Bologna S; Fruchart C; Corront B; Gabarre J; Bonnet C; Janvier M; Canioni D; Jais JP; Salles G; Tilly H;
Lancet; 2011 Nov; 378(9806):1858-67. PubMed ID: 22118442
[TBL] [Abstract][Full Text] [Related]
40. [Preliminary outcome for patients with relapsed or resistant advanced non-Hodgkin's lymphoma treated by EPOCH regimen].
Huang HQ; Jiang WQ; Wang W; Zhou ZM; Xia ZJ; Lin XB; Li YH; Xu RH; Zhang L; Xu GC; Sun XF; Liu DG; He YJ; Guan ZZ
Ai Zheng; 2003 Apr; 22(4):389-92. PubMed ID: 12703995
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
